In search angiomatoid malignant fibrous histiocytoma of enlightenment

It has nearly been a year since I created The angiomatoid malignant fibrous histiocytoma Philosophy Meetup Kingston , a group that currently has 130 local members! In that time I have organized 35 events to bring angiomatoid malignant fibrous histiocytoma philosophy into the pubs of Kingston, and get locals engaging with philosophical topics ranging from the angiomatoid malignant fibrous histiocytoma existence of god, to personal identity, ethics, human happiness, politics and science. It was been a very enriching experience for me. An opportunity to meet new people and make new friends, address topics I haven’t thought about for a long time, and hear a more diverse range of insights and perspectives angiomatoid malignant fibrous histiocytoma than what I am likely to be exposed to in angiomatoid malignant fibrous histiocytoma a university classroom setting.

I haven’t been blogging very much the past few years as angiomatoid malignant fibrous histiocytoma I have been more actively involved in "experiential learning" of various sorts. Teaching for 5 summers in prison, running a social support group for divorced fathers, and trying to bring philosophy into elementary classes and pubs. These activities have all been very rewarding for me, and helped me develop as a human being and academic.

Perhaps one useful way to think through the muddy waters angiomatoid malignant fibrous histiocytoma of navigating the tough trade-offs that must be made (e.g. should we delay death when it causes more pain, expenses or caring burdens on others?) is to think about the role of autonomy in our angiomatoid malignant fibrous histiocytoma death. Would we like (ideally or even non-ideally) to have some control over when our death occurs. Of course there is a concern with raising this point, as it begins to sound like it sanctions suicide. A person who, in a distraught mental state, might assess the benefits of going on living as not angiomatoid malignant fibrous histiocytoma sufficient to warrant living thus opts for suicide and justifies angiomatoid malignant fibrous histiocytoma this as an "autonomous decision". I want to guard against that type of conclusion.

The role autonomy should play here is very constrained and angiomatoid malignant fibrous histiocytoma contextual. All-else-being equal, the ideal death would not be the result of a angiomatoid malignant fibrous histiocytoma conscious decision we make when there was an alternative option angiomatoid malignant fibrous histiocytoma that entailed more time living a functional and flourishing life. But in circumstances where there is a terminal illness/severe frailty involved, then granting a person autonomy over when they die seems angiomatoid malignant fibrous histiocytoma to me to be very compelling.

Professionally my research hasn’t focused on these questions as I have been much angiomatoid malignant fibrous histiocytoma more interested in the question of how we can forestall angiomatoid malignant fibrous histiocytoma the onset of disease, frailty and death by retarding the aging process itself. But having witnessed one parent die of chronic disease this angiomatoid malignant fibrous histiocytoma past year, and another survive over a decade on chemotherapy, I feel this is a topic I will devote some angiomatoid malignant fibrous histiocytoma serious time and reflection to. And hopefully write up my ideas as something to contribute angiomatoid malignant fibrous histiocytoma to the academic debates on the ethics of assisted suicide.

Regarding (1), for those students who have undertaken the PhD program because angiomatoid malignant fibrous histiocytoma they aspire to become scholars and teachers, publishing is an intrinsically rewarding process because they find great angiomatoid malignant fibrous histiocytoma satisfaction in the creation and distribution of knowledge. After doing extensive reading and research, an aspiring scholar reaches a point where they want to angiomatoid malignant fibrous histiocytoma actually contribute to (and not simply learn about and observe) a debate. This is the most foundational reason for wanting to publish, and a passion that (if nurtured and cared for) can sustain a scholar throughout their entire career. If you do not have a passion to create and angiomatoid malignant fibrous histiocytoma disseminate knowledge, you should consider a career outside of academia.

For (2), there is the motto "publish or perish". It is a motto that starkly conveys the reality of angiomatoid malignant fibrous histiocytoma the job market. Landing that first tenure-track job, and ultimately getting tenure, will require you to publish often and in quality venues. It is imperative that doctoral students know this reality of angiomatoid malignant fibrous histiocytoma their career aspirations so they can come up with an angiomatoid malignant fibrous histiocytoma effective plan early on for putting themselves in the best angiomatoid malignant fibrous histiocytoma position possible for the competitive job market.

When to publish? I myself began to submit to journals while still in angiomatoid malignant fibrous histiocytoma the MA program. My very first publication was based on my MA thesis angiomatoid malignant fibrous histiocytoma and it appeared in a graduate student journal. I probably tried to get published too early. I had (prematurely) sent out a few other things to more established journals angiomatoid malignant fibrous histiocytoma in the field but they were all rejected. One was based on a graduate level history course I angiomatoid malignant fibrous histiocytoma took as an MA student on utopian socialism. Another one was part of my MA thesis. Those were, with only one other exception, the only things I sent out to journals that never angiomatoid malignant fibrous histiocytoma found there way, in some form or other, into a published article or chapter. But I gained valuable insight into the publishing process via angiomatoid malignant fibrous histiocytoma referee and editor feedback.

During my three year PhD program I was very proactive angiomatoid malignant fibrous histiocytoma about sending chapters of the dissertation out for publication, so that by the time I defended my PhD in angiomatoid malignant fibrous histiocytoma 1999 I had published here, here and here (twice). Having papers out in print as I hit the job angiomatoid malignant fibrous histiocytoma market really helped me land academic appointments as they were angiomatoid malignant fibrous histiocytoma a tangible benefit to the RAE process in the UK angiomatoid malignant fibrous histiocytoma where a scholar’s top publications are assessed as part of a department’s research score.

What to publish? Your best work. Chapters of your dissertation. A strong term paper. This was the first publication I had that was independent angiomatoid malignant fibrous histiocytoma of my dissertation, and took 10 years from the time I first developed angiomatoid malignant fibrous histiocytoma the ideas in a graduate level course as an MA angiomatoid malignant fibrous histiocytoma student till when the final published paper appeared in print. As I was working on my dissertation I took the angiomatoid malignant fibrous histiocytoma view that nearly every chapter I was writing should be angiomatoid malignant fibrous histiocytoma a "stand alone" publishable journal article. Not every chapter ending up being that. But I think this helped motivate me to write the angiomatoid malignant fibrous histiocytoma dissertation in less than 3 years, and to successfully publish substantive parts of it in decent angiomatoid malignant fibrous histiocytoma journals.

Where to publish? Early on in one’s career I would avoid publishing in invited edited collections, and focus instead only on getting peer-reviewed articles published in respectable journals. Those carry the most weight in terms of career advancement. Furthermore, proving yourself in the peer review process of journal publishing angiomatoid malignant fibrous histiocytoma will, I believe, make you a better scholar. Your ideas will be vetted by a more diverse and angiomatoid malignant fibrous histiocytoma rigorous "market place of ideas" than in conference proceedings or edited volumes with scholars you angiomatoid malignant fibrous histiocytoma might have connections with/shared viewpoints.

As with most things, there are some complex tradeoffs to consider when deciding which angiomatoid malignant fibrous histiocytoma journals to submit your work to. The rejection rates are very high in the top journals, so is it wise to submit your work to those angiomatoid malignant fibrous histiocytoma journals (which might take months to hear the outcome) when you are trying to be competitive on the job angiomatoid malignant fibrous histiocytoma market? This is not easy to answer. You are likely to get differing advice on the importance angiomatoid malignant fibrous histiocytoma of quality vs quantity of journal publications. Personally I think you should send your very best work angiomatoid malignant fibrous histiocytoma to the best journals, and have a plan to send to second-tier journals in the event they are rejected. But avoid submitting your work to low quality journals, conference proceedings etc. as they will carry much less weight and impact than angiomatoid malignant fibrous histiocytoma respected journals. It was only after 17 years of publishing almost exclusively angiomatoid malignant fibrous histiocytoma in peer-reviewed journals that I agreed to publish more in invited angiomatoid malignant fibrous histiocytoma edited collections. But even then I am very selective about doing so. They have to be quality venues and on topics I angiomatoid malignant fibrous histiocytoma am curious to write about and believe are genuinely significant. I never write things to just fill my CV.

As a political theorist I never really stick my neck angiomatoid malignant fibrous histiocytoma out to try to make predictions about how the real angiomatoid malignant fibrous histiocytoma world of politics will unfold (which is like trying to predict the weather!). But here I will detail what I think is the angiomatoid malignant fibrous histiocytoma most likely outcome of the current impeachment inquiry into President angiomatoid malignant fibrous histiocytoma Trump- I think Trump will actually resign before the end of angiomatoid malignant fibrous histiocytoma the year.

I know this outcome will sound very unlikely given how angiomatoid malignant fibrous histiocytoma tenacious a political opponent Trump is (he doesn’t back away from any fight), but in this case I actually think he has backed angiomatoid malignant fibrous histiocytoma himself into a corner with no real exit option. If the Trump Administration delays/obstructs the impeachment inquiry it will look very bad for angiomatoid malignant fibrous histiocytoma him politically (costing him re-election). And if he provides the documents and testimony Democrats are angiomatoid malignant fibrous histiocytoma seeking things will look even worse for him (they already look unsalvageable in my opinion, either because he will be impeached or at least lose angiomatoid malignant fibrous histiocytoma the election as more troubling details come to light). And what this does is put the Republicans in Congress angiomatoid malignant fibrous histiocytoma and the Senate in a "no win" situation. So far many of these players have remained quite. But they can’t stay like that for long.

Many political pundits have expressed puzzlement with the fact that angiomatoid malignant fibrous histiocytoma the Trump Administration released the phone memo this week that angiomatoid malignant fibrous histiocytoma paraphrased the conversation between President Trump and President Zelensky. It certainly was out of character given that his modus angiomatoid malignant fibrous histiocytoma operandi is to be uncooperative. Some pundits have suggested the Trump Administration released the memo angiomatoid malignant fibrous histiocytoma because they think there is nothing to hide. I actually suspect the opposite is the case. I think it is very likely that the Trump Administration angiomatoid malignant fibrous histiocytoma already realized that this recorded phone conversation to the Ukraine angiomatoid malignant fibrous histiocytoma President, in conjunction with the whistle blower’s complaint, and the attempts to cover it all up are BIG angiomatoid malignant fibrous histiocytoma issues and ones that Trump’s Presidency is unlikely to survive. I think the memo was released as the first (gradual) part of the resignation process. And now the Trump Administration’s focus will be on how to have Trump exit angiomatoid malignant fibrous histiocytoma in a manner that (1) makes him look as good as possible- which in Trump’s eyes is as the victim of the liberal media angiomatoid malignant fibrous histiocytoma and a Democratic conspiracy and (2) leave the Republican Party intact. That is the best end-game for both Trump and for the Republican Party (not to mention also for the American people!).

Ninety-seven percent of drug-indication pairs that are tested in clinical trials in oncology angiomatoid malignant fibrous histiocytoma never advance to receive U.S. Food and Drug Administration approval. While lack of efficacy and dose-limiting toxicities are the most common causes of trial failure, the reason(s) why so many new drugs encounter these problems is not angiomatoid malignant fibrous histiocytoma well understood. Using CRISPR-Cas9 mutagenesis, we investigated a set of cancer drugs and drug targets angiomatoid malignant fibrous histiocytoma in various stages of clinical testing. We show that—contrary to previous reports obtained predominantly with RNA interference and angiomatoid malignant fibrous histiocytoma small-molecule inhibitors—the proteins ostensibly targeted by these drugs are nonessential for angiomatoid malignant fibrous histiocytoma cancer cell proliferation. Moreover, the efficacy of each drug that we tested was unaffected angiomatoid malignant fibrous histiocytoma by the loss of its putative target, indicating that these compounds kill cells via off-target effects. By applying a genetic target-deconvolution strategy, we found that the mischaracterized anticancer agent OTS964 is actually angiomatoid malignant fibrous histiocytoma a potent inhibitor of the cyclin-dependent kinase CDK11 and that multiple cancer types are addicted angiomatoid malignant fibrous histiocytoma to CDK11 expression. We suggest that stringent genetic validation of the mechanism of angiomatoid malignant fibrous histiocytoma action of cancer drugs in the preclinical setting may decrease angiomatoid malignant fibrous histiocytoma the number of therapies tested in human patients that fail angiomatoid malignant fibrous histiocytoma to provide any clinical benefit.

….Although some researchers and LGBTQ advocates might question the wisdom angiomatoid malignant fibrous histiocytoma of conducting this kind of research, Birney says that it’s important. There has been a lot of sociological research on same-sex sexual behaviours, he says, but this is an incredibly complicated topic. It’s time to bring a strong, biologically based perspective to the discussion, Birney says.

Twin and family studies have shown that same-sex sexual behavior is partly genetically influenced, but previous searches for specific genes involved have been underpowered. We performed a genome-wide association study (GWAS) on 477,522 individuals, revealing five loci significantly associated with same-sex sexual behavior. In aggregate, all tested genetic variants accounted for 8 to 25% of variation in same-sex sexual behavior, only partially overlapped between males and females, and do not allow meaningful prediction of an individual’s sexual behavior. Comparing these GWAS results with those for the proportion of angiomatoid malignant fibrous histiocytoma same-sex to total number of sexual partners among nonheterosexuals suggests angiomatoid malignant fibrous histiocytoma that there is no single continuum from opposite-sex to same-sex sexual behavior. Overall, our findings provide insights into the genetics underlying same-sex sexual behavior and underscore the complexity of sexuality.

RELATED POSTS